
This study explores innovative targeted therapies for advanced prostate, breast, and ovarian cancers using mesotrypsin and KLK6 proteases and help learn about novel APPI mutants (APPI-3M and APPI-4M) with therapeutic and imaging potential, including their favorable attributes for efficacy, safety, and manufacturability, supporting their role in tackling metastatic cancer.
Like
Save
Share